99mTc-CNDG SPECT/CT in Brain Tumors

Summary

The goal of this clinical trial is to evaluate the value of 99mTc-CNDG for diagnosis of brain tumors by comparing it with 18F-FDG-PET. The main questions it aims to answer are: 1. What is the diagnostic consistency between 99mTc-CNDG and 18F-FDG? 2. What is the correlation between the SUVmax value of 99mTc-CNDG and tumor type? Participants will: Receive18F-FDG-PET and 99mTc-CNDG examination within 2 weeks before surgery. Obtain pathological diagnosis by surgery or biopsy as the gold standard.

Eligibility

Inclusion Criteria:

* Patients with clinical diagnosis of brain tumor;
* Be at least 18 years old;
* The final pathological results could be obtained by surgery or biopsy;
* Informed consent and the ability to be followed up;
* Those who did not meet the exclusion criteria.

Exclusion Criteria:

* Insulin-dependent diabetes mellitus or fasting blood glucose \>7 mmol/L before 99mTc-CNDG injection;
* Severe liver or kidney disease (serum creatinine level \>3.0mg/dL or any liver enzyme level ≥ 5 times the upper limit of normal);
* Severe hypersensitivity or hypersensitivity to radiocontrast agents;
* Claustrophobia (inability to undergo SPECT/CT or PET/CT scans);
* Patients receiving radiotherapy and chemotherapy;
* Being pregnant or breastfeeding.

Conditions2

Browse More Trials